Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck, Lilly, J&J Pricing Practices Praised By AWP "Whistleblower"

Executive Summary

Merck, Lilly, Johnson & Johnson and DuPont are examples of manufacturers who do not market the "spread" between average wholesale prices and actual prices, Ven-A-Care President Zachary Bentley told a Congressional hearing on AWPs Sept. 21.

You may also be interested in...



Medi-Cal AWP fraud suit expands

California Attorney General sues 39 pharmaceutical manufacturers for reporting inflated prices to the state's Medi-Cal Medicaid program. The suit, filed Aug. 25 in U.S. District Court in Boston, is an expansion of a 2003 California whistleblower suit against Abbott and Wyeth. Suit adds 38 defendants; Wyeth was dropped from the list of defendants after further investigation, the AG's office said. The defendant includes a variety of manufacturers: including both brand firms (Amgen, GlaxoSmithKline, Bristol-Myers Squibb and Novartis) as well as generic firms (Roxane, Mylan, Sandoz and Teva). Notably absent from the suit are Lilly, Merck, Pfizer and Johnson & Johnson. The suit alleges that the firms defrauded the state by reporting inflated wholesale prices to pricing compendia, which Medi-Cal used to determine physician reimbursement rates. California is one of a number of states suing manufacturers for pricing fraud based on data provided by whistleblowing pharmacy Ven-A-Care (1"The Pink Sheet" Oct. 1, 2001, p. 12)...

Medi-Cal AWP fraud suit expands

California Attorney General sues 39 pharmaceutical manufacturers for reporting inflated prices to the state's Medi-Cal Medicaid program. The suit, filed Aug. 25 in U.S. District Court in Boston, is an expansion of a 2003 California whistleblower suit against Abbott and Wyeth. Suit adds 38 defendants; Wyeth was dropped from the list of defendants after further investigation, the AG's office said. The defendant includes a variety of manufacturers: including both brand firms (Amgen, GlaxoSmithKline, Bristol-Myers Squibb and Novartis) as well as generic firms (Roxane, Mylan, Sandoz and Teva). Notably absent from the suit are Lilly, Merck, Pfizer and Johnson & Johnson. The suit alleges that the firms defrauded the state by reporting inflated wholesale prices to pricing compendia, which Medi-Cal used to determine physician reimbursement rates. California is one of a number of states suing manufacturers for pricing fraud based on data provided by whistleblowing pharmacy Ven-A-Care (1"The Pink Sheet" Oct. 1, 2001, p. 12)...

Together Rx Cited In AWP Price-Fixing Suit; Amended Complaint Drops Merck

A class action suit alleges manufacturers participating in the Together Rx discount drug card program are involved in a conspiracy to increase the average wholesale price "spread" on products in the program

Related Content

UsernamePublicRestriction

Register

PS038595

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel